Abstract
SummaryThe clinical and microbiological efficacy, cost-per-patient and tolerability of teicoplanin were compared with those of vancomycin as empirical or secondline treatment of febrile neutropenic episodes in patients with hematologic malignancy or solid tumors. In terms of efficacy and cost teicoplanin and vancomycin were found equivalent, while teicoplanin is better tolerated and may be used effectively for treatment of out-patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
